GWM
ABUS icon

Geneos Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Geneos Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$3K – 2738
2021
Q4 		$3K Hold
1,000
– – ﹤0.01% 2504
2021
Q3 		$4K Hold
1,000
– – ﹤0.01% 2487
2021
Q2 		$2K Hold
1,000
– – ﹤0.01% 2632
2021
Q1 		$3K Hold
1,000
– – ﹤0.01% 2773
2020
Q4 		$3K Buy
+1,000
New +$3.5K ﹤0.01% 2591

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geneos Wealth Management's ABUS Position: Q1 2022 in Review

Geneos Wealth Management sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 1,000 shares — an estimated $3K sold.

Geneos Wealth Management first reported a position in ABUS in Q4 2020 and held it in 5 quarters. The position peaked at $4K in Q3 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Geneos Wealth Management reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 1,000 Arbutus Biopharma shares in Q1 2022, an estimated $3K.
  • Geneos Wealth Management first reported a position in Arbutus Biopharma in Q4 2020 and held it in 5 quarters.
  • Geneos Wealth Management's Arbutus Biopharma position peaked at $4K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.